De Novo Antibody Sequencing
De novo antibody sequencing is an advanced analytical technique that leverages high-resolution mass spectrometry (HRMS) and bioinformatics tools to accurately determine the complete amino acid sequence of antibodies. Unlike conventional genomic sequencing or antibody gene library methods, this approach directly analyzes the protein sequence, enabling precise sequence determination without relying on genetic templates. This capability addresses the challenges of recognizing antibody variable regions (CDRs) and has become particularly valuable in the development and production of monoclonal antibodies, chimeric antibodies, and humanized antibodies.
De novo antibody sequencing plays a pivotal role in biopharmaceutical research, diagnostic reagent development, and therapeutic antibody engineering. In antibody drug discovery, the amino acid sequence forms the foundation for antibody design and optimization. Through de novo sequencing, researchers can gain a comprehensive understanding of antibody structure, facilitating improvements in affinity, specificity, and stability. In biosimilar development, de novo sequencing ensures structural fidelity to the originator antibodies, supporting functional consistency and regulatory compliance. Additionally, this technology holds great potential in the development of immune diagnostic reagents and the investigation of autoimmune disease mechanisms.
Principles of De Novo Antibody Sequencing
The foundation of de novo antibody sequencing lies in analyzing antibody samples using high-resolution mass spectrometry to decode their primary amino acid sequence. The workflow consists of several key steps:
1. Antibody Digestion
Antibody molecules are enzymatically digested using a combination of proteases to generate overlapping peptide fragments, ensuring high sequence coverage.
2. Peptide Separation and Mass Spectrometry Analysis
High-performance liquid chromatography (HPLC) separates peptide fragments, which are subsequently analyzed using tandem mass spectrometry (LC-MS/MS) to obtain high-resolution peptide mass spectra.
3. Sequence Assembly
Bioinformatics tools are employed to align and assemble peptide data, reconstructing the complete antibody amino acid sequence, including variable regions (VH and VL) and constant regions of the heavy and light chains.
4. Post-Translational Modification Analysis
Key post-translational modifications (e.g., glycosylation, oxidation, deamination) are identified to ensure the integrity and accuracy of the sequencing results.
Key Considerations for De Novo Antibody Sequencing
1. Sample Purity
High sample purity is essential for efficient digestion and reliable mass spectrometry results. Impurities can interfere with peptide identification and sequence assembly.
2. Optimized Digestion Strategy
Utilizing multiple proteases enhances sequence coverage and reduces the risk of ambiguous or incomplete sequence reconstruction.
3. Mass Spectrometry Accuracy
High-resolution mass spectrometry is crucial for generating reliable peptide spectra, minimizing errors caused by instrument sensitivity limitations.
4. Advanced Bioinformatics Analysis
Robust bioinformatics tools are required for accurate sequence reconstruction and post-translational modification analysis, ensuring result reproducibility.
MtoZ Biolabs specializes in providing reliable and precise de novo antibody sequencing services. With extensive expertise in antibody purification, mass spectrometry analysis, and bioinformatics interpretation, we guarantee high-quality data and deliver comprehensive antibody sequence insights tailored to our clients' research and development needs.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
